These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 18272909)
21. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system. Rhee Fv Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275 [No Abstract] [Full Text] [Related]
22. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice. Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700 [TBL] [Abstract][Full Text] [Related]
23. Deletion of idiotype (Id)-specific T cells in multiple myeloma. Bogen B; Schenck K; Munthe LA; Dembic Z Acta Oncol; 2000; 39(7):783-8. PubMed ID: 11145433 [TBL] [Abstract][Full Text] [Related]
24. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Osterborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H Blood; 1998 Apr; 91(7):2459-66. PubMed ID: 9516146 [TBL] [Abstract][Full Text] [Related]
25. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812 [TBL] [Abstract][Full Text] [Related]
26. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma. Hollander N Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888 [TBL] [Abstract][Full Text] [Related]
29. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748 [TBL] [Abstract][Full Text] [Related]
30. Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine. Mellstedt H; Osterborg A Pathol Biol (Paris); 1999 Feb; 47(2):211-5. PubMed ID: 10192891 [TBL] [Abstract][Full Text] [Related]
31. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells]. Yin XR; Zhang M; Luo YY; Lin X; He PC; Chen LM; Cai RB; Guo GL Ai Zheng; 2005 Jun; 24(6):657-62. PubMed ID: 15946473 [TBL] [Abstract][Full Text] [Related]
32. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777 [TBL] [Abstract][Full Text] [Related]
33. Translational development of vaccination strategies in follicular NHL. Sakamaki I; Qin H; Kwak LW Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625 [TBL] [Abstract][Full Text] [Related]
34. Determination of idiotype-specific T cells in idiotype-vaccinated mice. Heyfets A; Haimovich J; Hollander N Immunol Lett; 2002 Mar; 80(3):207-13. PubMed ID: 11803054 [TBL] [Abstract][Full Text] [Related]
35. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
36. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. Kim SB; Baskar S; Kwak LW Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873 [TBL] [Abstract][Full Text] [Related]
37. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systems. Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A Haematologica; 2007 Jan; 92(1):110-4. PubMed ID: 17229643 [TBL] [Abstract][Full Text] [Related]
38. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Lee ST; Jiang YF; Park KU; Woo AF; Neelapu SS Expert Opin Biol Ther; 2007 Jan; 7(1):113-22. PubMed ID: 17150023 [TBL] [Abstract][Full Text] [Related]
39. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. Timmerman JM; Levy R J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787 [TBL] [Abstract][Full Text] [Related]
40. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing. Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]